FAQs

FAQs on Our Transaction with Novo Holdings

• What are the benefits of this transaction?

  As part of Novo Holdings, Catalent will benefit from access to additional capital and resources to provide enhanced services for the benefit of customers and patients. With Novo Holdings, Catalent will be even better positioned to execute our mission to develop, manufacture and supply products that help people live better and healthier lives.

• How will this transaction impact customers?

  While this transaction represents a change in ownership for Catalent, it does not change its business priorities.

  Catalent will maintain its Patient First culture and uphold the same stringent processes with respect to safety, quality and compliance, risk management, product development and launch, and reliable supply.

  We will continue to operate as a leading global, independent, full-service CDMO.

  Catalent and Novo Holdings, as well as Novo Nordisk, are all committed to continuing to deliver the same, or better, level of service to customers and to honoring all existing contracts and customer obligations.

  Likewise, all of us understand the importance of protecting customers’ intellectual property and have policies in place to safeguard customers’ confidential information. This will remain paramount.

• Following transaction close, will Catalent’s work at its remaining nearly 50 global sites change?

  No. As a private company under Novo Holdings’ ownership, Catalent will continue to operate as a leading global, independent, full-service CDMO and our remaining network of nearly 50 global sites will continue to:

  • Provide customers with the latest technology and capabilities, deep experience, scalable capacity, proven regulatory expertise, and commitment to excellence;
  • Partner closely with customers to successfully bring their products through development and clinical trials, and reliably supply their needs for commercial product launch and beyond;
  • Offer fill and finish services for sterile products for large and small molecules, including gene and cell therapies – areas in which Catalent continues to invest and expand; and
  • Work with customers to expand patient access to much needed treatments and cures.

• How will this transaction impact patients?

  Catalent will continue to be driven by its Patient First mindset, working with urgency to ensure that a reliable and high-quality supply of products is available for the patients who need them.

  Additionally, Catalent will benefit from Novo Holdings' partnership and support to help bring even better treatments to patients worldwide.

  Simply put, our priority to expanding patient access to much needed treatments and cures will remain the same.

• When is the transaction expected to close?

  The transaction is expected to close towards the end of calendar year 2024, subject to customary closing conditions, including receipt of required regulatory approvals. Following close, Catalent will continue to focus on its mission and success in delivering on our long-term objectives in life sciences innovation.

  Until the transaction closes, Catalent will remain an independent public company.

• What will happen to Catalent after the transaction closes? What does it mean that Catalent will operate as a private company post-close?

  Following transaction close, shares of Catalent will no longer trade on the New York Stock Exchange and Catalent will become a private company while continuing to serve customers as a global leading independent CDMO.

  Catalent has been a private company three times before. These historic business cycles of going public and going private have enabled Catalent to not just grow but to thrive for close to a century.

  As a private company, Catalent will maintain our Patient First culture and be even better positioned to ensure that a reliable and high-quality supply of products is available for the patients who need them.

• Will Alessandro Maselli continue to lead the Company following transaction close?

  Yes, Alessandro Maselli will continue to lead Catalent as President and CEO following the transaction close and looks forward to partnering with all of the Company’s employees and Novo Holdings in this next chapter.

• Is Novo Nordisk acquiring Catalent?

  No. Novo Holdings, a holding and investment company, is acquiring Catalent.

  In a separate transaction, following the close of Novo Holdings’ acquisition of Catalent, Novo Nordisk intends to acquire three of Catalent’s 50+ global sites located in Anagni, Italy; Bloomington, Indiana USA; and Brussels, Belgium from Novo Holdings.

• Is Novo Holdings the same company as Novo Nordisk?

  No. Novo Holdings is a global investment firm, which has a controlling interest in, but operates independently from, Novo Nordisk.

  In a separate transaction, following the close of Novo Holdings’ acquisition of Catalent, Novo Nordisk intends to acquire three of Catalent’s 50+ global sites located in Anagni, Italy; Bloomington, Indiana USA; and Brussels, Belgium from Novo Holdings.

  Novo Nordisk has noted that, upon closing of the deal, all employees at the three sites will transfer to Novo Nordisk and will play a key role in serving even more patients with injectable products.

  Following the closing of the transaction, Novo Holdings and Novo Nordisk will continue to be operated independently from each other, as they always have.

• What is Catalent’s role in the commercial manufacturing of injectable GLP-1 products?

  No GLP-1 products other than Novo Nordisk’s Wegovy are currently manufactured for commercial sale at the three Catalent sites that Novo Holdings plans to sell to Novo Nordisk.

  Additionally, Catalent has no role in the commercial manufacturing of Eli Lilly’s Zepbound and Mounjaro products.

• What types of companies does Novo Holdings invest in and own? What is Novo Holdings’ focus?

  As an investment firm, Novo Holdings is focused on long-term sustainable value creation through an engaged, supportive ownership approach. That means Novo Holdings is committed to working closely with Catalent’s management to grow the business and contribute the best way possible to their onward commercial success.

  Novo Holdings’ purpose is to invest in companies that are improving people’s health and the sustainability of the planet.

  Novo Holdings manages a portfolio of 170+ direct life science investments, 44% of which are U.S.-based companies.

  Over the past five years, Novo Holdings has deployed USD $9.2 billion into life sciences companies around the world, ranging from early-stage venture investments to larger, more established businesses like Catalent.

  Through its investments, Novo Holdings supports 9,800+ full time employees in the U.S.

• Do Novo Holdings and Catalent have similar values?

  Yes. Like Catalent, Novo Holdings is a mission-driven company – a big part of its mission is to invest in companies that address unmet medical needs, while also prioritizing operational excellence.

  Novo Holdings’ high regard for Catalent’s Patient First culture, deep life science expertise and proven investment track record were all important factors that reinforced our determination that it was the right partner for Catalent.

• Where can I find additional information?

  Between now and transaction close, we will work to provide updates when we have them, subject to Catalent’s obligations as a public company. As always, if you have further questions, please reach out to your usual contact.